A new synthetic steroid, osaterone acetate (TZP-4238), increases cortical bone mass and strength by enhancing bone formation in ovariectomized rats

Journal of Bone and Mineral Research

Volumn 12, Issue 4, 1997, Pages 590-597

  Fuse, Hiroaki ^a   Fukumoto, Seiji ^b   Sone, Hideyuki ^a   Miyata, Yoshiko ^a   Saito, Tomoyuki ^a,d   Nakayama, Konosuke ^b   Takahashi, Hiroo ^a   Matsumoto, Toshio ^d   Ogata, Etsuro ^c  

^a Grelan Pharmaceutical Co Ltd   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ESTRADIOL; OSATERONE ACETATE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; CONTROLLED STUDY; CORTICAL BONE; FEMALE; HORMONAL THERAPY; METAPHYSIS; NONHUMAN; OSSIFICATION; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TRABECULAR BONE;

ANDROGEN ANTAGONISTS; ANIMALS; BODY WEIGHT; BONE DENSITY; CALCIUM; CHLORMADINONE ACETATE; ESTRADIOL; FEMALE; FEMUR; ORGAN SIZE; OSTEOGENESIS; OVARIECTOMY; PHOSPHATES; RATS; RATS, WISTAR; TIBIA;

EID: 0030938127     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1997.12.4.590     Document Type: Article

References (17)

1. Eastell R, Riggs BL 1987 Treatment of osteoporosis. Obstet Gynecol Clin N Am 14:77-88.
2. Riggs BL, Melton LD 1992 The prevention and treatment of osteoporosis. New Engl J Med 327:620-627.
3. Resnick NM, Greenspan SL 1989 'Senile' osteoporosis reconsidered. JAMA 261:1025-1029.
4. Shibata K, Takegawa S, Koizumi N, Yamakoshi N, Shimazawa E 1992 Antiandrogen. I. 2-Azapregnane and 2-oxapregnane steroids. Chem Pharm Bull 40:935-941.
5. Murakoshi M, Inada R, Makino M, Suzuki M, Mieda M, Honma S, Yamanaka H 1990 Effect of anti-androgen (TZP4238) on steroid-induced canine prostatic hyperplasia. Light and electron microscopic investigations. Acta Pathol Jpn 40:871-879.
6. Hata K, Miura M, Fukumoto S, Matsumoto T 1995 Assay of serum pyridinoline: A potential marker for bone resorption. Clin Chim Acta 235:221-227.
7. Hata K, Tokuhiro H, Miura M 1994 Precision assay of bonetype alkaline phosphatase. Jpn J Clin Chem 23:26-31.
8. Finch JL, Rapp N, Martin KJ, Slatopolsky E 1992 A new sensitive homologous radioimmunoassay for amino-terminal parathyroid hormone in the rat. J Bone Miner Res 7:229-233.
9. Nakamura T, Hanada K, Tamura M, Shibanushi T, Nigi H, Tagawa M, Fukumoto S, Matsumoto T 1995 Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats. Endocrinology 136:1276-1284.
10. Wallenstein S, Zucker CL, Fleiss JL 1980 Some statistical methods useful in circulation research. Circ Res 47:1-9.
11. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R 1993 Anabolic actions of parathyroid hormone on bone. Endocrine Rev 14:690-709.
12. Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM 1994 Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. New Engl J Med 331:1618-1623.
13. Mosekilde L, Mosekilde L 1990 Sex differences in age-related changes in vertebral body size, density and biomechanical competence in normal individuals. Bone 11:67-73.
14. Mosekilde L 1989 Sex differences in age-related loss of vertebral trabecular bone mass and structure-Biomechanical consequences. Bone 10:425-432.
15. Vermeulen A 1991 Clinical review 24: Androgens in the aging male. J Clin Endocrinol Metab 73:221-224 (review).
16. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU 1994 Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63-69.
17. Ke HZ, Simmons HA, Pirie CM, Crawford DT, Thompson DD 1995 Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 136:2435-2441.